161 related articles for article (PubMed ID: 37643784)
1. Pan-cancer Analysis Reveals Cancer-dependent Expression of SOX17 and Associated Clinical Outcomes.
Xu LI; Bai Y; Cheng Y; Sheng X; Sun D
Cancer Genomics Proteomics; 2023; 20(5):433-447. PubMed ID: 37643784
[TBL] [Abstract][Full Text] [Related]
2. Decreased expression of SOX17 is associated with tumor progression and poor prognosis in breast cancer.
Fu DY; Tan HS; Wei JL; Zhu CR; Jiang JX; Zhu YX; Cai FL; Chong MH; Ren CL
Tumour Biol; 2015 Sep; 36(10):8025-34. PubMed ID: 25971583
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic regulation of Wnt signaling pathway gene SRY-related HMG-box 17 in papillary thyroid carcinoma.
Li JY; Han C; Zheng LL; Guo MZ
Chin Med J (Engl); 2012 Oct; 125(19):3526-31. PubMed ID: 23044318
[TBL] [Abstract][Full Text] [Related]
4. Identifying SOX17 as a Sensitive and Specific Marker for Ovarian and Endometrial Carcinomas.
Shaker N; Chen W; Sinclair W; Parwani AV; Li Z
Mod Pathol; 2023 Jan; 36(1):100038. PubMed ID: 36788073
[TBL] [Abstract][Full Text] [Related]
5. Prognostic and clinicopathological significance of TMEFF2, SMOC-2, and SOX17 expression in endometrial carcinoma.
Alabiad MA; Harb OA; Hefzi N; Ahmed RZ; Osman G; Shalaby AM; Alnemr AA; Saraya YS
Exp Mol Pathol; 2021 Oct; 122():104670. PubMed ID: 34339705
[TBL] [Abstract][Full Text] [Related]
6. Reduced expression of SRY-box containing gene 17 correlates with an unfavorable melanoma patient survival.
Lu J; Zhang G; Cheng Y; Tang Y; Dong Z; McElwee KJ; Li G
Oncol Rep; 2014 Dec; 32(6):2571-9. PubMed ID: 25310020
[TBL] [Abstract][Full Text] [Related]
7. SOX17 overexpression sensitizes chemoradiation response in esophageal cancer by transcriptional down-regulation of DNA repair and damage response genes.
Kuo IY; Huang YL; Lin CY; Lin CH; Chang WL; Lai WW; Wang YC
J Biomed Sci; 2019 Feb; 26(1):20. PubMed ID: 30777052
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA‑21‑5p promotes epithelial to mesenchymal transition by targeting SRY‑box 17 in endometrial cancer.
Wang C; Li Q; He Y
Oncol Rep; 2020 Jun; 43(6):1897-1905. PubMed ID: 32236579
[TBL] [Abstract][Full Text] [Related]
9. SOX17 is a tumor suppressor in endometrial cancer.
Zhang Y; Bao W; Wang K; Lu W; Wang H; Tong H; Wan X
Oncotarget; 2016 Nov; 7(46):76036-76046. PubMed ID: 27738313
[TBL] [Abstract][Full Text] [Related]
10. SOX17 restrains proliferation and tumor formation by down-regulating activity of the Wnt/β-catenin signaling pathway via trans-suppressing β-catenin in cervical cancer.
Li L; Yang WT; Zheng PS; Liu XF
Cell Death Dis; 2018 Jul; 9(7):741. PubMed ID: 29970906
[TBL] [Abstract][Full Text] [Related]
11. Sox7, Sox17, and Sox18 Cooperatively Regulate Vascular Development in the Mouse Retina.
Zhou Y; Williams J; Smallwood PM; Nathans J
PLoS One; 2015; 10(12):e0143650. PubMed ID: 26630461
[TBL] [Abstract][Full Text] [Related]
12. Sox17, the canonical Wnt antagonist, is epigenetically inactivated by promoter methylation in human breast cancer.
Fu DY; Wang ZM; Li-Chen ; Wang BL; Shen ZZ; Huang W; Shao ZM
Breast Cancer Res Treat; 2010 Feb; 119(3):601-12. PubMed ID: 19301122
[TBL] [Abstract][Full Text] [Related]
13. Low SOX17 expression is a prognostic factor and drives transcriptional dysregulation and esophageal cancer progression.
Kuo IY; Wu CC; Chang JM; Huang YL; Lin CH; Yan JJ; Sheu BS; Lu PJ; Chang WL; Lai WW; Wang YC
Int J Cancer; 2014 Aug; 135(3):563-73. PubMed ID: 24407731
[TBL] [Abstract][Full Text] [Related]
14. Dysregulation of SOX17/NRF2 axis confers chemoradiotherapy resistance and emerges as a novel therapeutic target in esophageal squamous cell carcinoma.
Hsieh CH; Kuan WH; Chang WL; Kuo IY; Liu H; Shieh DB; Liu H; Tan B; Wang YC
J Biomed Sci; 2022 Oct; 29(1):90. PubMed ID: 36310172
[TBL] [Abstract][Full Text] [Related]
15. Low SOX17 expression: prognostic significance in de novo acute myeloid leukemia with normal cytogenetics.
Tang CY; Lin J; Qian W; Yang J; Ma JC; Deng ZQ; Yang L; An C; Wen XM; Zhang YY; Qian J
Clin Chem Lab Med; 2014 Dec; 52(12):1843-50. PubMed ID: 24955525
[TBL] [Abstract][Full Text] [Related]
16. Upregulated miR-194-5p suppresses retinal microvascular endothelial cell dysfunction and mitigates the symptoms of hypertensive retinopathy in mice by targeting SOX17 and VEGF signaling.
Wan Q; Liu H; Xu Y; Zhang Q; Tao L
Cell Cycle; 2023 Feb; 22(3):331-346. PubMed ID: 36200131
[TBL] [Abstract][Full Text] [Related]
17. Loss-of-function mutations of SOX17 lead to YAP/TEAD activation-dependent malignant transformation in endometrial cancer.
Wang M; Yan Q; Song Y; Zhang Z; Chen X; Gao K; Wan X
Oncogene; 2023 Jan; 42(4):322-334. PubMed ID: 36446891
[TBL] [Abstract][Full Text] [Related]
18. MRP3-Mediated Chemoresistance in Cholangiocarcinoma: Target for Chemosensitization Through Restoring SOX17 Expression.
Lozano E; Asensio M; Perez-Silva L; Banales JM; Briz O; Marin JJG
Hepatology; 2020 Sep; 72(3):949-964. PubMed ID: 31863486
[TBL] [Abstract][Full Text] [Related]
19. Notch pathway targets proangiogenic regulator Sox17 to restrict angiogenesis.
Lee SH; Lee S; Yang H; Song S; Kim K; Saunders TL; Yoon JK; Koh GY; Kim I
Circ Res; 2014 Jul; 115(2):215-26. PubMed ID: 24755984
[TBL] [Abstract][Full Text] [Related]
20. Induction and down-regulation of Sox17 and its possible roles during the course of gastrointestinal tumorigenesis.
Du YC; Oshima H; Oguma K; Kitamura T; Itadani H; Fujimura T; Piao YS; Yoshimoto T; Minamoto T; Kotani H; Taketo MM; Oshima M
Gastroenterology; 2009 Oct; 137(4):1346-57. PubMed ID: 19549530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
